1. Scrip
  2. >>COVID-19

Moderna Takes Middle Ground On Pricing With 100 Million Dose US Agreement

Looking At $30.50 Per Course

 
• By Ian Haydock

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.

Aerial overhead view of trailer trucks delivering a vaccine. 3D rendering
Another Supply Deal As Vaccine Race Intensifies • Source: Shutterstock

Moderna, Inc.’s shares jumped more than 8% in after-hours trading on 11 August after the vaccine developer announced it had reached an agreement with the US government to supply an initial 100 million doses of its mRNA coronavirus candidate mRNA-1273.

Up to $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.